Vertex Pharmaceuticals (VRTX) Retained Earnings (2009 - 2026)

Vertex Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $14.6 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 21326.43% year-over-year to $14.6 billion; the TTM figure through Mar 2026 stood at $14.6 billion (up 21326.43% YoY), while the FY2025 annual figure was -$15.9 million, down 100.17% from the prior year.
• Retained Earnings was $14.6 billion for Q1 2026 at Vertex Pharmaceuticals, up from -$15.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $14.6 billion in Q1 2026 to a low of -$101.1 million in Q2 2025.
• Historically, Retained Earnings has averaged $4.7 billion across 5 years, with a median of $4.0 billion in 2022.
• The sharpest annual moves came in 2023 and 2025: Retained Earnings surged 1267700.0% in 2023, then slumped 101.32% in 2025.
• A 5-year view of Retained Earnings shows it stood at $800000.0 in 2022, then soared by 1267700.0% to $10.1 billion in 2023, then retreated by 5.28% to $9.6 billion in 2024, then plunged by 100.17% to -$15.9 million in 2025, then jumped by 91869.81% to $14.6 billion in 2026.
• The last three Retained Earnings figures came in at $14.6 billion (Q1 2026), -$15.9 million (Q4 2025), and -$64.5 million (Q3 2025), per Business Quant data.